Zoledronic acid infusion for prevention and treatment of osteoporosis

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 353-360

  Sunyecz, John A ^a,b  

^a Laurel Highlands Ob/Gyn   (United States)

^b MenopauseRx Inc   (United States)

Author keywords

Fractures; Intravenous bisphosphonate; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARACETAMOL; PLACEBO; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DEMINERALIZATION; BONE REMODELING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; MYALGIA; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 78650729974     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/IJWH.S7322     Document Type: Review

References (50)

1. misctextInternational Osteoporosis Foundation/misctext. Facts and Statistics About Osteoporosis and Its Impact. http://www.iofbonehealth.org/facts-andstatistics.html. Accessed 2010 Jun 30.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in theUnited States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
3. International Osteoporosis Foundation. Invest in Your Bones. Quality of Life: Why Prevent the First Fracture? http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/quality_of_life.pdf. Accessed 2010 Jun 30.
4. Chapurlat RD, Delmas PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006; 2:211-219.
5. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103:7829-7834.
6. Kimmel DB. Mechanism of action, pharmacokinetic, and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022-1033.
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-1008.
8. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
9. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone. 2007;41:882-887.
10. Weycker D, Macarios D, Edlesberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18: 271-277.
11. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-818.
12. Reclast injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2010.
13. Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005;20:557-563.
14. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18:805-810.
15. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005;16:134-141.
16. National Osteoporosis Foundation. Fast facts on osteoporosis [fact sheet]. http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed 2010 Jun 30.
17. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229-238.
18. National Osteoporosis Foundation. Advocacy News and Updates. America's Bone Health: The State of Osteoporosis and Low Bone Mass. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/advocacy/prevalence/index.htm. Accessed 2010 Jun 30.
19. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407-413.
20. Cranney A, Jama SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007; 177:575-580.
21. Gabriel SE, Tosteson ANA, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-330.
22. Hallberg I, Rosenqvist AM, Kartous L, Löfman O, Wahlström O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int. 2004;15:834-841.
23. Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporos Int. 2005:16:78-85.
24. Kanis JA, Burlet N, Cooper C, et al; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published correction appears in Osteoporos Int. 2008;19: 1103-1104]. Osteoporos Int. 2008;19:399-428.
25. Cadarette SM, Katz JN, Brookhart MA, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol. 2008;35: 319-326.
26. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed 2010 Jun 30.
27. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.
28. Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007;23:2517-2529.
29. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23:2193-2203.
30. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023-1031.
31. Cooper A, Drake J, Brankin E; the PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896-905.
32. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.
33. Janner M, Muhlbauer RC, Fleisch H. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int. 1991;49:280-283.
34. Morr S, Cuartas E, Alwattar B, Lane JM. How much calcium is in your drinking water? A survey of calcium concentrations in bottled and tap water and their significance for medical treatment and drug administration. HSS J. 2006;2:130-135.
35. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356: 1809-1822.
36. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799-1809.
37. Orwoll E, Miller PD, Adachi JD, et al. Efficacy and safety of a onceyearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. Epub 2010 Apr 30.
38. Siris ES, Miller PD, Barrett-Conner E, et al. Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286:2815-2822.
39. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
40. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17: 1404-1409.
41. McClung M, Miller P, Recknor C, et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet Gynecol. 2009;114:999-1007.
42. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]. Ann Intern Med. 2006;144: 753-761.
43. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22: 1479-1491.
44. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349-353.
45. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-231.
46. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Lowenergy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350.
47. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008; 93:2948-2952.
48. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304-1306.
49. McClung M, Recker R, Miller P, et al. Intravenous zoledro nic acid5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
50. Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol. 2010;29:1079-1084.